APVO - Aptevo Therapeutics

[heth247]

Anybody still following this company? It is trading below net cash now. They did a nasty stock offer of $1 recently, doubled the share count, but it will buy them more time. And now it is trading at $0.75. I guess the question is will they run out of money before any of the drug in their pipeline make it to market.

[Spekulatius]

I own a few shares unfortunately. I failed to sell it when they clinical trial failed and the investment thesis wasn’t there any more. I agree it’s cheap now, but the cash on hand is certainly insufficient to bring a drug to market. I regard this as a lottery ticket.

[patience_and_focus]

Bumping up this thread. 

 

Aptevo is a biotech company which currently has one candidate in clinical trial and a couple about to enter clinical trials. Its bi-specific platform "ADAPTIR" has been around for quite some time (history goes back to Trubion acquired by Emergent which then spun-off as Aptevo and subsequently one of earlier lead candidate failed). Operates in the currently hot field of cancer therapies. One of their main candidates is APVO436 is in AML/MDS and has shown some activity and just released press indicates clean toxicity profile.  On the corporate side, seems like an activist hedge fund already tried to take it private for $50 / share last year but was rebuffed. Currently the share price sits at around $25 / share. 

 

Given the new information on APVO436 in the Phase I and potential for buyout, would love to get input from others on the merit of this as an investment. I do not consider it a high probability winner but the risk / reward seems to be certainly skewed towards potential upside.

 

Disclosure: Had bought some stocks with a small allocation in 2019 but sold out at the end of 2020 for decent gains. Desire to get into this again given the new developments and current stock price.